Age Not a Deterrent to Immunotherapy for Malignant Melanoma

Share this content:
Study participants >65 years of age who were treated with immunotherapy had better median PFS.
Study participants >65 years of age who were treated with immunotherapy had better median PFS.

Patients >65 years of age with metastatic melanoma who are treated with immunotherapy do not have an increased risk for immune-related adverse events (AEs), according to the results of a recent single-center, retrospective cohort study published in JAMA Dermatology.

The investigators sought to evaluate whether age is associated with clinical outcomes among patients with metastatic melanoma treated with immunotherapy. A total of 92 patients with metastatic melanoma who were treated between January 2007 and February 2016 with ipilimumab, nivolumab, or pembrolizumab were enrolled in the study. The primary end points included overall survival (OS) and progression-free survival (PFS). OS was defined as the time from treatment initiation to death from any cause.

PFS was defined as the time from treatment initiation to progressive disease or death from any cause — whichever occurred first. Secondary end points included the percentage of immune-related AEs and the type of AEs based on patient age.

Overall, 92 patients were enrolled in the study for a total of 120 lines of treatment. There were 54 patients in the cohort ≤65 years of age (44% women; mean age, 48.1±12.5 years) and 38 participants in the cohort >65 years of age (34% women; mean age, 74.8±6.9 years). Mean follow-up duration beginning at treatment initiation was 12.5 months.

Participants >65 years of age who were treated with immunotherapy (ipilimumab and antiprogrammed cell death protein 1) had better median PFS (4.8 months [95% CI, 3.5-6.8] vs 3.4 months [95% CI, 2.7-3.0], respectively; P =.04) and median OS (not reached [95% CI, 16.1-not reached] vs 10.1 months [95% CI, 7.3-21.1], respectively; P =.009) than those ≤65 years of age. The occurrence of common immune-related AEs was similar in both cohorts.

The investigators concluded that age should not be a limiting factor for immunotherapy in patients with malignant melanoma. Additional studies are warranted to confirm these findings and describe the underlying mechanisms involved.

Reference

Perier-Muzet M, Gatt E, Péron J, et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol. 2018;154(1):82-87.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs